Status:
UNKNOWN
Pamiparib in mCRPC With HRD or BRCA1/2 Mutation
Lead Sponsor:
Sun Yat-sen University
Conditions:
Metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy of a PARP inhibitor, Pamiparib, in metastatic castration-resistant prostate cancer patients with homologous recombination deficiency or BRCA 1 or 2 ...
Detailed Description
This is a single arm, open-label, single center, phase II trial, assessing the efficacy of a PARP inhibitor, Pamiparib, in 50 progressing metastatic castration-resistant prostate cancer patients with ...
Eligibility Criteria
Inclusion
- ≥18 years old, male
- Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma without neuroendocrine differentiation of the prostate. Mixed histology is accepted, except for small cell carcinoma.
- Have a deleterious mutation in BRCA1/2 , or HRD score ≥ 9.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- BPI\<4
- Metastatic Castration-resistant Prostate Cancer (mCRPC): Presence of measurable target lesion according to RECIST criteria v1.1
- Male subject has been surgically or medically sterilized and has serum testosterone level ≤1.73nmol/L.
- Unsterilized male subject uses an acceptable method of contraception (defined as a barrier method with spermicide) to prevent pregnancy during the duration of the study and for 6 months after the last dose of Pamiparib.
- Experienced disease progression after having received at least 1 prior next-generation androgen receptor-targeted therapies, for metastatic castration-resistant disease.
- Capable of swallowing the whole capsule.
- Subjects must have normal organ and bone marrow function at baseline, as defined below:
- Hemoglobin ≥ 9.0 g/dL at least 28 days after transfusion . Absolute neutrophil count ≥ 1.5 × 10\^9/L. Platelet count ≥ 100 × 10\^9/L. Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) specified. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase/alanine aminotransferase (ALT) serum glutamic pyruvic transaminase) ≤ 3 × the specified ULN, unless liver metastases are present, in which case it must be ≤ 5 × ULN.
- Agree to sign informed consent form
- Agree not to participate in other interventional trials during this trial.
Exclusion
- Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
- Acute toxicity (CTCAE \> grade 2) due to prior cancer therapy.
- Received chemotherapy, endocrine therapy, biotherapy, radionuclide therapy, immunotherapy, experimental drugs, proprietary anticancer drugs or Chinese herbal medicines within 5 (if known) half-lives or 14 days(if unknown) prior to the first day of taking Pamiparib; For bisphosphonates or approved bone targeting therapy, Pamiparib must be administered at a steady dose for ≥28 days prior to the first day of taking Pamiparib.
- Received radiation therapy within 21 days.
- Prior treatment with any PARP inhibitor. Prior chemotherapy with mitoxantrone or platinum-based chemotherapy or cyclophosphamide. Prior treatment with sipuleucel-T or immune check point inhibitors are allowed.
- Subjects with major surgery within 2 weeks before starting study treatment. Subjects expected to receive major surgery during the trial.
- Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
- Symptomatic and/or untreated central nervous system metastases
- Immunocompromised subjects, such as those with positive human immunodeficiency virus (HIV) serology.
- Subjects with known active hepatitis (e.g. hepatitis B or C).
- The subject has a serious cardiovascular disease. ( For example, but not limited to: uncontrolled arrhythmia, myocardial infarction)
- Concomitant use of strong CYP3A inducers or moderate CYP3A inducers . If half-lives is known, a 5 half-lives washout period is required before the start of Pamiparib therapy and a 2-week washout period is required when the half-lives is unknown.
- History of intolerance to Pamiparib capsule excipients
- Excluded by investigators
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 20 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05327621
Start Date
May 1 2022
End Date
March 20 2025
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060